Latest on the Availability of New Anti-CGRP Medications

By April 14, 2020October 22nd, 2020CGRP, Health, Latest, MAI News

Latest on the Availability of the new anti-CGRP Medications in Ireland

The following information is correct as of Thursday the 22nd of October 2020…

There are 2 main approaches for targeting CGRP in migraine: monoclonal antibodies given by injection to prevent attacks and small absorbable tablets for acute and preventative treatment. Medications act by either blocking a receptor called the calcitonin gene-related peptide receptor (CGRP-R), or binding to the substance (CGRP) and not allowing it to reach the nerve.

CGRP – What is it and what does it do?

  • It’s a substance that is released in the trigeminal nerve
  • It spikes during migraine
  • CGRP dilates blood vessels
  • Degrades mast cells (cells which control inflammation during allergic reactions)
  • Creates an inflammatory fluid in the blood vessels

For more information see Prof. Peter Goadsby’s Interview from the European Academy of Neurology Congress 2016 on our website

There are several pharmaceutical companies involved in the manufacture of CGRP and other drugs. The main ones are; Amgen/Novartis Inc, Teva, Eli Lilly, Alder/Lundbeck, Allergan and Biohaven Pharmaceuticals.


Here are the names of some of the Anti-CGRP Medications which will hopefully enter the Irish market soon;

CGRP Compound Brand Name Pharma Company Administered Preventative/Acute
Erenumab Aimovig Amgen/Novartis Auto-injector once a month Preventative
Fremanezumab Ajovy Teva Subcutaneous injection once a month or quarterly Preventative
Galcanezumab Emgality Eli Lilly Subcutaneous injection once a month Preventative
Eptinezumab Yvepti Alder/Lundbeck Intravenous injection once every 3 months Preventative

What’s available and what’s coming?


  • The Marketing Authorisation was granted in Ireland in the Summer 2018 and Novartis is currently awaiting the results of the Health Technology Assessment for the Irish licensing application. The Migraine Association wrote the supporting patient organisation document as part of this process.
  • Erenumab was available on a managed access programme but this programme unfortunately closed to new patients in June 2019
  • NCPE has recommended Erenumab for chronic migraine only – still awaiting HSE verdict


  • Teva’s version of anti-CGRP medication, Fremanezumab (Ajovy) became available on a ‘Free of Charge’ programme, which is similar to the managed access programme, from July 2019. New patients can only access Fremanezumab through their Neurologists, and only after meeting certain criteria, one of which is having tried and failed three or four other preventative medications.
  • Teva is also awaiting the results of the Health Technology Assessment for the Irish licensing application. The Migraine Association wrote the supporting patient organisation document as part of this process.
  • NCPE has recommended Fremanezumab for both Episodic and Chronis Migraine – still awaiting HSE verdict

Eli Lilly:

  • Lilly’s Galcanezumab is next, but we have no news as to its availability yet. There is the strong possibility that Galcanezumab will also be made available to treat those who suffer with Cluster Headache too, the only one of the new medications to say this!
  • Lilly’s Lasmiditan (Reyvow) is not an anti-CGRP but the first of a new group of headache medicines that are called “ditans.” Just like a triptan, Lasmiditan can stop a migraine when taken at the appropriate time, but unlike a triptan, Lasmiditan does not have vasoconstricting properties and may be helpful for people for whom triptans are contraindicated due to cardiovascular problems.

Side Effects:

So far, the side-effects reported for both Erenumab and Fremanezumab are anecdotal but seem so far to be few and mild with mostly pain at the injection site, possibly a skin rash near the site. Other people have reported having more frequent headaches for a short while but less severe in intensity. Others have felt no difference until being prescribed a higher or double dose of the medication. As they are relatively new medications, long-term effects are unknown.

Much of the information that is currently available in relation to these new anti-CGRP medications applies to the UK or the US, e.g. Both Erenumab and Fremanezumab have been passed by the Scottish Medicines consortium for use in migraine in Scotland with Erenumab passed only for people with chronic migraine and Fremanezumab for both chronic and episodic migraine, for patients who have failed to respond to 3 other preventatives.

For further information and updates on the latest information on the availability of the new Anti-CGRP medications in Ireland keep an eye on our website

For general updates you can go to where you can sign up for a newsletter every few weeks.

See our earlier updates…

January 2019

August 2018